ClinicalTrials.gg
RecruitingNCT07816692Updated Sep 30, 2026

iDose TR Administration in an Office-Based Surgery Setting

An observational study in Open Angle Glaucoma (OAG) and Ocular Hypertension (OHT), sponsored by Glaukos Corporation. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Glaukos Corporation · Observational

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 43 studies in Glaucoma, Open-Angle by Glaukos Corporation — 7 open to participants now, 10 under way, 2 of them phase 3. Glaucoma, Open-Angle · Glaukos Corporation.

Started
2026
with 1 other
Observational
5 of 43
2 open now
Registered
43rd of 43
by date

Among the 43 studies in Glaucoma, Open-Angle by Glaukos Corporation, this one is one of 2 that started in 2026, is one of 5 observational ones, and was the 43rd registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

7 of the 43 studies in Glaucoma, Open-Angle by Glaukos Corporation are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Glaucoma, Open-Angle by Glaukos Corporation, or all of them as a file.
02

Study summary

Clinical in-use observational trial to evaluate the administration of iDose TR (travoprost intracameral implant) in an office-based surgery setting.

Read the detailed description

This study is a multicenter, single arm, open-label trial in adult subjects with open-angle glaucoma or ocular hypertension. The objective of the study is to assess the safety profile of iDose TR administration in an office-based surgery setting.

03

Conditions studied

  • Open Angle Glaucoma (OAG)
  • Ocular Hypertension (OHT)

Keywords

  • Glaucoma
  • Ocular Hypertension
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults 18 years of age or older with open-angle glaucoma or ocular hypertension

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of Open angle glaucoma (OAG) or ocular hypertension (OHT)

Exclusion criteria

Exclusion Criteria:

  • Prior administration of iDose TR or administration of an intracameral implant in the study eye
  • Active ocular infection or inflammation
  • History of to travoprost or implant components
  • Recent ocular surgery
  • Uncontrolled systemic disease
  • Any condition preventing safe implantation
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30 participants (estimated)
Patient registry
No

Groups and cohorts

  • iDose TR

    Travoprost Intracameral Implant

    Combination Product: iDose TR (travoprost intracameral implant) 75 µg

Interventions

06

What researchers measure

Primary outcomes

  1. Successful administration of iDose TR in an office-based surgical setting.

    Number of subjects that received iDose TR in an office-based surgical setting by the Investigator.

    Time frame: 3 months

07

Study locations

1 of 1 sites recruiting
  • Glaukos Investigative Site
    Austin, Texas 78746, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Mar 2027, 10 months after the start.

Of 53 observational studies under Glaucoma, Open-Angle, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12. This study's planned 10 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2026
First posted
Sep 14, 2026
StartActual
May 13, 2026
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2027
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: criteria formatting
1 update, last Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Minor edits only
    + 1 other change: criteria formatting

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07816692
Responsible party
Sponsor
First posted
Sep 14, 2026
Start date
May 13, 2026
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Sep 30, 2026

Study contacts

Study Director
Contact
ClinicalResearch@glaukos.com
949-739-8749

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion